Welcome to our dedicated page for STANDEX INTERNATIONAL CORP/DE/ SEC filings (Ticker: SXI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on STANDEX INTERNATIONAL CORP/DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into STANDEX INTERNATIONAL CORP/DE/'s regulatory disclosures and financial reporting.
Standex International Corporation reported the results of its Annual Meeting of Stockholders. Shareholders elected two directors to three-year terms ending at the 2028 annual meeting: Thomas E. Chorman (For: 9,623,949; Against: 1,253,659; Abstain: 1,454) and Andy L. Nemeth (For: 10,859,557; Against: 17,250; Abstain: 2,255).
Stockholders approved the advisory vote on executive compensation with 10,660,832 votes For, 213,117 Against, and 5,113 Abstain. They also ratified Deloitte & Touche LLP as the Company’s independent public accountants for the fiscal year ending June 30, 2026, with 10,943,594 votes For, 359,021 Against, and 1,619 Abstain. A total of 11,304,234 common shares were represented at the meeting.
Standex International (SXI) reported Q1 FY2026 results for the three months ended September 30, 2025. Net sales were $217.4 million, up from $170.5 million, led by Electronics at $110.6 million and Engraving at $35.8 million. Diluted EPS was $1.25 versus $1.53 a year ago as expenses increased.
Operating income was $29.6 million and included $6.0 million of restructuring costs and $0.4 million of acquisition costs. Interest expense rose to $8.9 million from $1.0 million, reducing income from continuing operations to $15.8 million. Cash from operations was $16.8 million. Cash and equivalents were $98.7 million, and long‑term debt was $544.6 million.
The company advanced integration of recent deals: McStarlite (cash consideration $57.0 million net of cash acquired) and the Amran/Narayan Group (final allocation: identifiable intangibles $136.0 million, goodwill $298.4 million). An interest rate swap effective August 30, 2025 fixes $225 million of borrowings at 3.48% through August 30, 2028. A quarterly dividend of $0.32 per share was declared.
Standex International Corporation (SXI) filed an 8-K to furnish its earnings press release for the first quarter ended September 30, 2025. The press release is provided as Exhibit 99 and is incorporated by reference. The filing uses Item 2.02 (Results of Operations and Financial Condition) and also includes the Exhibit 104 Cover Page Inline XBRL file.
The company notes that the communication contains forward-looking statements subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, with risk factors referenced in the accompanying release and the company’s Form 10-K for the fiscal year ended June 30, 2025.
Standex International (SXI) reported an insider transaction by its VP, Chief HR Officer. A Form 4 shows 111 shares of common stock were forfeited at $244.87 on 10/24/2025 to cover taxes tied to the vesting of previously issued restricted stock. Following the transaction, the officer directly owned 7,311 shares.
Standex International Corporation (SXI) reported a routine insider equity grant. A director acquired 639 shares of Common Stock on 10/21/2025 at a stated price of $0, reflecting a restricted stock award under the company’s 2018 Omnibus Incentive Plan.
The award vests three years after the date of grant. Following this transaction, the reporting person’s beneficial ownership stands at 14,229 shares, held directly.
Standex International (SXI): A company director reported a grant of 639 restricted shares of common stock on 10/21/2025 at $0 under the company’s 2018 Omnibus Incentive Plan. The award is scheduled to vest three years after the grant date.
Following this transaction, the director’s beneficial ownership stands at 12,905.4464 shares, held directly. This filing records an equity compensation award and does not indicate any open‑market purchase or sale.
Standex International (SXI) reported an insider equity award. Director Alan J. Glass acquired 639 shares of common stock on 10/21/2025 via a restricted stock grant under the Company’s 2018 Omnibus Incentive Plan. The award carries a $0 price, reflecting a grant rather than an open‑market purchase, and vests three years after the date of grant.
Following this transaction, the reporting person beneficially owned 14,424 shares, held directly.
Standex International (SXI) reported an insider equity award. A company director acquired 639 shares of Common Stock on 10/21/2025 at $0 via a restricted stock grant under the 2018 Incentive Plan.
The award vests three years after the date of grant. After this transaction, the director beneficially owns 4,698.089 shares, held directly.
Standex International (SXI) disclosed a Form 4 indicating a director received 639 shares of common stock on 10/21/2025 as a restricted stock grant under the company’s 2018 Omnibus Incentive Plan.
The award was recorded at $0 per share and vests three years after the grant date. Following this transaction, the reporting person beneficially owns 6,285 shares, held directly.
Standex International (SXI) reported an insider equity award. A director received a grant of 639 shares of common stock on 10/21/2025, coded as an acquisition under the company’s 2018 Omnibus Incentive Plan. The grant price was $0, and the restricted stock is scheduled to vest three years after the grant date.
Following this grant, the reporting person beneficially owns 6,639 shares, held directly. This filing reflects routine director compensation in equity rather than an open‑market purchase or sale.